Ulrich Canzler
Overview
Explore the profile of Ulrich Canzler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montegut C, Falandry C, Cinieri S, Cropet C, Montane L, Rousseau F, et al.
Oncologist
. 2024 Dec;
PMID: 39673779
Background: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life...
2.
Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, et al.
Arch Pathol Lab Med
. 2024 Dec;
PMID: 39648143
Context.—: A correlation between the morphology of ovarian high-grade serous carcinomas (HGSOCs) and BRCA mutations has been previously reported. Objective.—: To investigate, beyond BRCA, the association between the morphology of...
3.
Ramachandran D, Tyrer J, Kommoss S, DeFazio A, Riggan M, Webb P, et al.
NPJ Genom Med
. 2024 Mar;
9(1):19.
PMID: 38443389
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous...
4.
Heublein S, Pfisterer J, du Bois A, Anglesio M, Aminossadati B, Bhatti I, et al.
Lab Invest
. 2023 Dec;
104(4):100321.
PMID: 38154497
With more novel drugs being approved for the treatment of ovarian carcinoma, the question remains to what extent patients benefit from antiangiogenic treatment with bevacizumab, either in combination with poly-(ADP-ribose)...
5.
Chekerov R, Arndt T, Pietzner K, Canzler U, Wimberger P, Strauss H, et al.
J Cancer Res Clin Oncol
. 2023 Mar;
149(10):7637-7649.
PMID: 37000264
Purpose: Pazopanib has promising antiangiogenetic activity in solid cancers. The investigator-initiated phase I/II trial evaluated the combination of Topotecan with Pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer (ROC). Methods:...
6.
Mirza M, Lindahl G, Mahner S, Redondo A, Fabbro M, Rimel B, et al.
Cancer Res Commun
. 2023 Mar;
2(11):1436-1444.
PMID: 36970052
Significance: We retrospectively evaluated the mutational profile of HRR genes in tumor samples from 331 patients from the non-germline -mutated cohort of the phase III NOVA trial of patients with...
7.
Sabatier R, Rousseau F, Joly F, Cropet C, Montegut C, Frindte J, et al.
Eur J Cancer
. 2023 Jan;
181:42-52.
PMID: 36634389
Background: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance...
8.
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, et al.
J Clin Oncol
. 2022 Nov;
41(4):893-902.
PMID: 36332161
Purpose: To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer. Methods: In this multicenter, open-label, randomized...
9.
Gonzalez-Martin A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, et al.
Eur J Cancer
. 2022 Sep;
174:221-231.
PMID: 36067615
Background: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo plus bevacizumab in newly diagnosed, advanced ovarian cancer. We report the prespecified main...
10.
Fumet J, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267497
Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment...